# US 8,771,944 B2 · Use of micro-RNA as a biomarker of immunomodulatory drug activity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,771,944 B2
- Document ID: US8771944B2
- Status: Granted
- Kind: B2
- Application number: 13/104,927
- Filed: 2011-05-10
- Published: 2012-02-09
- Granted: 2014-07-08
- Earliest claimed: 2007-12-20
- Assignees: Celgene Corporation
- Applicants: Gregory D. Ferguson; Helen Brady; Kyle Chan; Normand R. Richard
- Inventors: Gregory D. Ferguson; Helen Brady; Kyle Chan; Normand R. Richard
- Web page: https://patentgrep.com/patent/US8771944B2

## CPC

- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/136: Screening for pharmacological compounds
- C12Q 2600/158: Expression markers
- C12Q 2600/178: miRNA, siRNA or ncRNA
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Methods of determining the activity of an immunomodulatory compound by measuring the presence of an miRNA in a sample are disclosed. Additionally disclosed are methods of assessing the patient compliance in patients treated with an immunomodulatory compound.

## Claims

### Claim 1

A method for identifying an immunomodulatory compound, comprising:
a) obtaining a biological sample from a patient;
b) contacting a cancer cell from the biological sample with the compound;
c) detecting the presence of a miRNA expression, wherein the miRNA is miR-143, or miR-145 in the cancer cell;
d) quantifying the level of expression of the miRNA in the cancer cell and the level of the same miRNA in a cell not contacted with the compound; and
e) assessing the difference in the level of the miRNA expression in the cancer cell contacted with the compound and in the cell not contacted with the compound to identify the immunomodulatory compound, wherein an increased level of expression of one or more of the miRNA correlates with an immunomodulatory activity.

### Claim 2 (depends on 1)

The method of claim 1, wherein the increased level of expression of one or more of the miRNA correlates with the compound's efficacy in treating cancer.